[Treatment of pulmonary tuberculosis in patients resistant to major drugs with second line drugs].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000494:pharmacology*; D002208:Caproates / Q000494:pharmacology; D002648:Child; D003523:Cycloserine / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D004977:Ethambutol / Q000494:pharmacology; D005000:Ethionamide / Q000494:pharmacology; D006801:Humans; D007612:Kanamycin / Q000494:pharmacology; D008875:Middle Aged; D009536:Niacinamide / Q000494:pharmacology; D011718:Pyrazinamide / Q000494:pharmacology; D011719:Pyrazines; D012293:Rifampin / Q000494:pharmacology; D013882:Thiosemicarbazones / Q000494:pharmacology; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D014756:Viomycin / Q000494:pharmacology
D000995:Antitubercular Agents; D002208:Caproates; D011719:Pyrazines; D013882:Thiosemicarbazones; D009536:Niacinamide; D011718:Pyrazinamide; D007612:Kanamycin; D004977:Ethambutol; D003523:Cycloserine; D005000:Ethionamide; D012293:Rifampin; D014756:Viomycin
El tratamiento de la tuberculosis pulmonar en pacientes resistentes a drogas myores por drogas de segunda línea.